CA2868500C — Needle assisted jet injection administration of testosterone compositions
Assigned to Antares Pharma Inc · Expires 2020-04-21 · 6y expired
What this patent protects
Provided is a powered injector and use thereof, the injector comprising a housing, a chamber disposed within the housing and configured to receive a composition, and a needle operatively associated with the chamber, the composition comprising a preservative-free unit dose of test…
USPTO Abstract
Provided is a powered injector and use thereof, the injector comprising a housing, a chamber disposed within the housing and configured to receive a composition, and a needle operatively associated with the chamber, the composition comprising a preservative-free unit dose of testosterone or a pharinaceutically acceptable ester or salt thereof and a pharmaceutically acceptable carrier for delivery of a subcutaneous injection to a mammal in need thereof, and wherein a delivered plasma level of testosterone is for maintenance thereafter between about 200 ng/dl and about 1800 ng/dl for a time period of at least one day.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.